CNP-104
Primary Biliary Cholangitis (PBC)
PreclinicalActive
Key Facts
Indication
Primary Biliary Cholangitis (PBC)
Phase
Preclinical
Status
Active
Company
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a mission-driven, publicly traded biotech dedicated to advancing the treatment of gastrointestinal diseases and redefining the standard of care. Its cornerstone achievement is the discovery, development, and commercialization of the first-in-class GC-C agonist LINZESS® (linaclotide), a blockbuster therapy for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's strategy centers on leveraging its proprietary GI platforms, commercial infrastructure, and deep scientific expertise to build a pipeline targeting organic GI diseases with high unmet need, including the late-stage development of apraglutide for short bowel syndrome.
View full company profileTherapeutic Areas
Other Primary Biliary Cholangitis (PBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Setanaxib | Calliditas Therapeutics | Phase 2 |
| CNP Program | COUR Pharmaceuticals | Unknown |
| RO-7011789 (Nidufexor) | Rohto Pharmaceutical | Phase 2 |
| IQIRVO® (elafibranor) | Ipsen | Marketed / Late-stage Study |
| Elafibranor (GFT505) | Genfit | Phase 3 |